ID   LL3_LASLA               Reviewed;          15 AA.
AC   C0HK44;
DT   02-NOV-2016, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2016, sequence version 1.
DT   02-JUN-2021, entry version 5.
DE   RecName: Full=Lasioglossin-3 {ECO:0000303|PubMed:19591185};
DE            Short=LL-III {ECO:0000303|PubMed:19591185};
OS   Lasioglossum laticeps (Bee).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Apoidea;
OC   Halictidae; Halictinae; Halictini; Lasioglossum; Evylaeus.
OX   NCBI_TaxID=88510 {ECO:0000303|PubMed:19591185};
RN   [1] {ECO:0000305}
RP   PROTEIN SEQUENCE, FUNCTION, SUBCELLULAR LOCATION, MASS SPECTROMETRY,
RP   IDENTIFICATION BY MASS SPECTROMETRY, STRUCTURE BY NMR, MUTAGENESIS OF
RP   1-VAL-ASN-2 AND GLY-8, AND AMIDATION AT LYS-15.
RC   TISSUE=Venom {ECO:0000303|PubMed:19591185};
RX   PubMed=19591185; DOI=10.1002/cbic.200900133;
RA   Cerovsky V., Budesinsky M., Hovorka O., Cvacka J., Voburka Z.,
RA   Slaninova J., Borovickova L., Fucik V., Bednarova L., Votruba I.,
RA   Straka J.;
RT   "Lasioglossins: three novel antimicrobial peptides from the venom of the
RT   eusocial bee Lasioglossum laticeps (Hymenoptera: Halictidae).";
RL   ChemBioChem 10:2089-2099(2009).
RN   [2] {ECO:0000305}
RP   FUNCTION, AND MUTAGENESIS OF VAL-1; 1-VAL-ASN-2; ILE-6; GLY-8 AND ILE-11.
RX   PubMed=22100226; DOI=10.1016/j.peptides.2011.11.002;
RA   Slaninova J., Mlsova V., Kroupova H., Alan L., Tumova T., Monincova L.,
RA   Borovickova L., Fucik V., Cerovsky V.;
RT   "Toxicity study of antimicrobial peptides from wild bee venom and their
RT   analogs toward mammalian normal and cancer cells.";
RL   Peptides 33:18-26(2012).
CC   -!- FUNCTION: Antimicrobial peptide which assumes an amphiphilic alpha-
CC       helix conformation upon contact with membranes (PubMed:19591185).
CC       Insertion into membranes involves Trp-3 (By similarity). Penetrates
CC       into cells once membrane has been permeated (PubMed:22100226). Active
CC       against Gram-negative bacteria E.coli (MIC=1.4 uM), P.aeruginosa
CC       (MIC=18.7 uM) and Gram-positive bacteria S.aureus (MIC=3.9 uM) and
CC       B.subtilis (MIC=0.7 uM) (PubMed:19591185). Has cytotoxic but no
CC       hemolytic activity (PubMed:19591185, PubMed:22100226). Binds DNA in
CC       vitro (By similarity). {ECO:0000250|UniProtKB:C0HK43,
CC       ECO:0000269|PubMed:19591185, ECO:0000269|PubMed:22100226}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19591185}.
CC   -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC       {ECO:0000305|PubMed:19591185}.
CC   -!- PTM: The C-terminal amidation is required for full activity.
CC       {ECO:0000269|PubMed:19591185}.
CC   -!- MASS SPECTROMETRY: Mass=1764.1; Mass_error=0.1; Method=Electrospray;
CC       Evidence={ECO:0000269|PubMed:19591185};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
PE   1: Evidence at protein level;
KW   Amidation; Antibiotic; Antimicrobial; Direct protein sequencing;
KW   DNA-binding; Secreted.
FT   PEPTIDE         1..15
FT                   /note="Lasioglossin-3"
FT                   /evidence="ECO:0000269|PubMed:19591185"
FT                   /id="PRO_0000437652"
FT   MOD_RES         15
FT                   /note="Lysine amide"
FT                   /evidence="ECO:0000269|PubMed:19591185"
FT   MUTAGEN         1..2
FT                   /note="VN->NV: Reduced activity against S.aureus and
FT                   P.aeruginosa. No effect on cytotoxicity."
FT                   /evidence="ECO:0000269|PubMed:19591185,
FT                   ECO:0000269|PubMed:22100226"
FT   MUTAGEN         1
FT                   /note="V->K,N: Reduced cytotoxicity."
FT                   /evidence="ECO:0000269|PubMed:22100226"
FT   MUTAGEN         6..8
FT                   /note="ILG->VLA: No effect on cytotoxicity."
FT                   /evidence="ECO:0000269|PubMed:22100226"
FT   MUTAGEN         6
FT                   /note="I->II: Reduced cytotoxicity."
FT                   /evidence="ECO:0000269|PubMed:22100226"
FT   MUTAGEN         8
FT                   /note="G->A: Slightly increased activity against S.aureus
FT                   and B.subtilis, reduced activity against P.aeruginosa.
FT                   Shows hemolytic activity. Slightly increased cytotoxicity."
FT                   /evidence="ECO:0000269|PubMed:19591185,
FT                   ECO:0000269|PubMed:22100226"
FT   MUTAGEN         8
FT                   /note="G->K: Slightly increased activity against E.coli,
FT                   reduced activity against S.aureus and P.aeruginosa. Shows
FT                   hemolytic activity. Slightly decreased cytotoxicity."
FT                   /evidence="ECO:0000269|PubMed:19591185,
FT                   ECO:0000269|PubMed:22100226"
FT   MUTAGEN         8
FT                   /note="G->P: Reduced antimicrobial activity except against
FT                   E.coli. Almost complete loss of cytotoxicity."
FT                   /evidence="ECO:0000269|PubMed:19591185,
FT                   ECO:0000269|PubMed:22100226"
FT   MUTAGEN         11
FT                   /note="I->K: Strongly reduced cytotoxicity."
FT                   /evidence="ECO:0000269|PubMed:22100226"
SQ   SEQUENCE   15 AA;  1766 MW;  2604A73CD4C7E7B6 CRC64;
     VNWKKILGKI IKVVK